Halassy subsequently underwent a year of trastuzumab therapy and remains cancer-free, marking 45 months without recurrence!
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose ...
Beata Halassy, an expert infectious disease researcher, treated her own stage 3 breast cancer by injecting the tumour with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback